Core Laboratories NV (CLB) stands as a leading provider of specialized reservoir optimization services and products in the oil and gas industry, focusing on enhancing reservoir characterization and maximizing production efficiency. Leveraging advanced technologies and proprietary analytical methods, the company delivers innovative solutions that prioritize sustainability and environmental responsibility. With a strong global presence, Core Labs is strategically positioned to seize new growth opportunities and effectively navigate the challenges of an evolving energy landscape, making it a compelling choice for institutional investors seeking long-term value in the sector.
| Revenue (TTM) | $519.18M |
| Gross Profit (TTM) | $101.32M |
| EBITDA | $57.13M |
| Operating Margin | 7.36% |
| Return on Equity | 9.05% |
| Return on Assets | 4.45% |
| Revenue/Share (TTM) | $11.26 |
| Book Value | $5.94 |
| Price-to-Book | 2.10 |
| Price-to-Sales (TTM) | 1.11 |
| EV/Revenue | 1.375 |
| EV/EBITDA | 11.39 |
| Quarterly Earnings Growth (YoY) | -41.20% |
| Quarterly Revenue Growth (YoY) | -4.30% |
| Shares Outstanding | $45.88M |
| Float | $45.23M |
| % Insiders | 1.43% |
| % Institutions | 117.50% |
Volatility is currently contracting
Investors looking for stocks in the Oil and Gas - Field Services sector might want to consider either Drilling Tools International Corp. (DTI) or Core Laboratories (CLB). But which of these two stocks is more attractive to value investors?
Core Laboratories stock looks cheaper after a 47.1% six-month selloff, but falling earnings and geopolitical pressure keep the near-term case cautious.
CLB's Q2 earnings top estimates despite lower revenues and profit as Production Enhancement strength offsets Reservoir Description weakness.
Core Laboratories NYSE: CLB reported second-quarter 2026 revenue of $124.6 million, up more than 2% from the prior quarter but down 4% from a year earlier, as stronger completion-product sales partly offset disruptions to its service business from conflicts in the Middle East and Russia-Ukraine.
Core Laboratories Inc. (CLB) Q2 2026 Earnings Call Transcript
REVENUE OF $ 124.6 MILLION, UP 2% SEQUENTIALLY AND DOWN 4% YEAR-OVER-YEAR OPERATING INCOME OF $ 9.2 MILLION; EX-ITEMS, $9.4 MILLION, UP 42% SEQUENTIALLY AND DOWN 36% YEAR-OVER-YEAR GAAP EARNINGS PER SHARE OF $0.13; EPS EX-ITEMS OF $0.11, UP 85% SEQUENTIALLY AND DOWN 42% YEAR-OVER-YEAR FREE CASH FLOW OF $ 3.1 MILLION COMPANY REPURCHASED 214,712 SHARES OF COMMON STOCK, FOR $2.7 MILLION AGGREGATE PURCHASE PRICE COMPANY ANNOUNCES Q3 2026 QUARTERLY DIVIDEND HOUSTON, July 29, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") reported second quarter 2026 revenue of $124,600,000. Core's operating income was $9,200,000, with earnings per diluted share ("EPS") of $0.13, all in accordance with U.S. generally accepted accounting principles ("GAAP").
CLB's Q2 may reflect resilient international activity and tariff insulation, but weaker reservoir description results and higher costs could weigh.
Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CLB struggles with ongoing headwinds from lower completion activity, operational disruptions, inflationary costs, weaker margins and projected earnings decline in 2026.
HOUSTON, June 30, 2026 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its second quarter 2026 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CLB and any ticker you trade — then tracks every position and per-strategy win rate.
